Compare stocks

Ipsen S.A. is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. The company focuses on the development and commercialization of innovative medicines in targeted therapeutic areas such as oncology, neuroscience, and rare diseases. Ipsen's key products include Somatuline, a treatment for neuroendocrine tumors and acromegaly, and Dysport, used for movement disorders and aesthetic indications. Founded in 1929 by Henri Beaufour, Ipsen has since expanded its presence worldwide, with a strategic emphasis on specialty care and the development of differentiated products. The company leverages its scientific expertise and research capabilities to sustain its competitive position in the biopharmaceutical industry.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.